Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome-Reference-Cited by-同舟云学术

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome

Published:2021-05 Issue:5 Volume:21 Page:338-344
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Morita Kiyomi,Jabbour Elias,Ravandi Farhad,Borthakur Gautam,Khoury Joseph D.^ORCID,Hu Shimin^ORCID,Garcia-Manero Guillermo^ORCID,Wierda William,Issa Ghayas,Daver Naval,Pemmaraju Naveen,Montalban-Bravo Guillermo,Soltysiak Kelly A.,Pierce Sherry^ORCID,Bueso-Ramos Carlos,Cortes Jorge^ORCID,Sasaki Koji^ORCID

Funder

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017

2. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial;Cortes;J Clin Oncol,2016

3. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016

4. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial;Cortes;J Clin Oncol,2018

5. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report;Journal of Medical Case Reports;2024-08-18

2. Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors;Medical Oncology;2023-07-13

3. Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia;Frontiers in Oncology;2022-10-06

4. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia;International Journal of Hematology;2022-09-10

5. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects;Cancers;2022-05-21